K. Surrey

1.5k total citations · 1 hit paper
9 papers, 1.2k citations indexed

About

K. Surrey is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, K. Surrey has authored 9 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Physiology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology and Allergy. Recurrent topics in K. Surrey's work include Asthma and respiratory diseases (8 papers), Allergic Rhinitis and Sensitization (5 papers) and Respiratory and Cough-Related Research (3 papers). K. Surrey is often cited by papers focused on Asthma and respiratory diseases (8 papers), Allergic Rhinitis and Sensitization (5 papers) and Respiratory and Cough-Related Research (3 papers). K. Surrey collaborates with scholars based in United Kingdom, Switzerland and United States. K. Surrey's co-authors include Martin Blogg, S. Hedgecock, Marc Humbert, Jean Bousquet, Sância Ramos, Raymond G. Slavin, K.M. Beeh, H. Fox, Richard Beasley and Jon G. Ayres and has published in prestigious journals such as CHEST Journal, Journal of Allergy and Clinical Immunology and Allergy.

In The Last Decade

K. Surrey

8 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

2004 839 citations Marc Humbert, Richard Beasley et al. Allergy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K. Surrey United Kingdom	4	1.1k	816	646	127	80	9	1.2k
K.M. Beeh Germany	4	847 0.8×	665 0.8×	427 0.7×	98 0.8×	62 0.8×	13	898
Paul J. Rowe United States	14	613 0.6×	329 0.4×	282 0.4×	181 1.4×	25 0.3×	79	875
Yanping Wu United States	7	920 0.8×	628 0.8×	250 0.4×	275 2.2×	25 0.3×	17	999
Juby A. Jacob‐Nara United States	14	548 0.5×	246 0.3×	327 0.5×	138 1.1×	23 0.3×	112	801
Cris Roxas United Kingdom	12	576 0.5×	483 0.6×	156 0.2×	124 1.0×	22 0.3×	38	650
Amr Radwan United States	11	283 0.3×	168 0.2×	156 0.2×	79 0.6×	14 0.2×	42	474
Tracy Bridges United States	3	259 0.2×	252 0.3×	107 0.2×	26 0.2×	48 0.6×	3	332
Paul G. Solari United States	11	226 0.2×	173 0.2×	92 0.1×	42 0.3×	14 0.2×	20	443
Laurence Gozalo United States	6	262 0.2×	262 0.3×	40 0.1×	31 0.2×	25 0.3×	14	351
Miguel Villarreal United States	7	143 0.1×	176 0.2×	133 0.2×	44 0.3×	12 0.1×	12	408

Countries citing papers authored by K. Surrey

Since Specialization

Citations

This map shows the geographic impact of K. Surrey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Surrey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Surrey more than expected).

Fields of papers citing papers by K. Surrey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Surrey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Surrey. The network helps show where K. Surrey may publish in the future.

Co-authorship network of co-authors of K. Surrey

This figure shows the co-authorship network connecting the top 25 collaborators of K. Surrey. A scholar is included among the top collaborators of K. Surrey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Surrey. K. Surrey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Busse, William W., Helen Fox, K. Surrey, Robert Maykut, & Colin Reisner. (2006). Clinically Relevant Improvements in Asthma-Related Quality of Life in Patients Receiving Omalizumab as Add-On Therapy. Journal of Allergy and Clinical Immunology. 117(2). S8–S8. 1 indexed citations

2.

Slavin, Raymond G., H. Fox, K. Surrey, & Colin Reisner. (2006). Factors Predictive of Future Clinically Significant Exacerbations in Severe Asthma. Journal of Allergy and Clinical Immunology. 117(2). S274–S274. 2 indexed citations

3.

Slavin, Raymond G., et al.. (2005). Omalizumab add-on therapy significantly reduces asthma exacerbations in patients with inadequately controlled severe persistent asthma despite GINA 2002 step 4 therapy: INNOVATE. Journal of Allergy and Clinical Immunology. 115(2). S76–S76. 2 indexed citations

4.

Humbert, Marc, Richard Beasley, Jon G. Ayres, et al.. (2004). Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 60(3). 309–316. 839 indexed citations breakdown →

5.

Vignola, A M, Marc Humbert, Jean Bousquet, et al.. (2004). Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 59(7). 709–717. 309 indexed citations

6.

Dahl, Ronald, Jon G. Ayres, S. Hedgecock, et al.. (2004). Efficacy of omalizumab, an anti-IgE antibody, in patients with concomitant moderate-severe allergic asthma and persistent allergic rhinitis. Journal of Allergy and Clinical Immunology. 113(2). S37–S37. 2 indexed citations

7.

Harnest, Ulf, LP Boulet, S. Hedgecock, et al.. (2004). Omalizumab, an anti-IgE antibody, improves both asthma- and rhinitis-related quality of life in patients with concomitant moderate-severe disease. Journal of Allergy and Clinical Immunology. 113(2). S176–S176. 3 indexed citations

8.

Boulet, Louis‐Philippe, Giorgio Walter Canonica, Ronald Dahl, et al.. (2003). Omalizumab, an Anti-IgE Antibody, Provides Parallel Improvements in Symptoms of Allergic Asthma and Perennial Allergic Rhinitis in Patients With Both Diseases: The SOLAR Stud. CHEST Journal. 124(4). 105S–105S. 4 indexed citations

9.

Busse, William W., Jonathan Corren, Bobby Q. Lanier, et al.. (2002). Omalizumab improves asthma-specific quality of life (QoL): An analysis of data from 1071 patients. Journal of Allergy and Clinical Immunology. 109(1). S291–S291. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact